ArticleCytopathology : official journal of the British Society for Clinical Cytology2025
The Methylation Test Is Highly Sensitive for HPV-Associated Endocervical Adenocarcinoma and Could Be Helpful as a Cytological Ancillary Test in Women With a PAP-Smear Diagnosis of Severe Glandular Lesion (AGC-NEO+).
Article in Cytopathology : official journal of the British Society for Clinical Cytology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Global Comparative Review of Guidelines for Cervical Adenocarcinoma In Situ.Life (Basel, Switzerland) · 2026Review
- Diagnostic Accuracy of DNA Methylation Markers for Detecting Cervical Precancer and Cervical Cancer: A Systematic Review and Meta-analysis.Archives of academic emergency medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThe limitations of PAP smears in diagnosing severe cervical glandular lesions motivate the development of ancillary methods to facilitate their detection. This prospective cytology-histology and molecular study aims to investigate methylation test performance by establishing the test sensitivity and its relevance to patient management.
methodLBC samples were prospectively acquired after 3 months following the primary conventional PAP-smear screening diagnosis of AGC-NEO (atypical glandular cells, favour neoplastic) and AIS. An HPV test and methylation test were performed. Corresponding subsequent biopsy reports were collected.
resultsSeven hundred and seventy Pap tests were signed out as AGC-NEO+. Complete study data were available for 85 cases (AIS in 46 cases, EA in 39 cases) that were further analysed. The methylation test was positive in 95.3% (81/85) cases, negative in 3.5% (3/85, AIS in two cases, EA in one case) and unanalysable in one sample (1.2%). HPV genotyping revealed a multi-infection rate of 29%. The presence of HPV types 16 and 18 was detected in 84% (72/85) of lesions, and HPV type 45 in 12% (10/85).
conclusionsThe methylation test shows a high sensitivity of 95.3% and reliably identifies histologically confirmed AIS+ lesions. This argues for further investigation into its performance characteristics and consideration of its use, especially as a pre-surgical triaging test in sensitive cases if the AIS+ lesion is suspected in pregnant women or nullipara.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.